Comparison Overview
ICOTYDE™ (icotrokinra) tablets for US HCPs
ICOTYDE™ (icotrokinra) tablets for US HCPs
N/A
Last Update: 22/04/2026
Official page for US healthcare professionals. Please see Important Safety Information, full Prescribing Information, and Medication Guide linked below. ICOTYDE Full Prescribing Information: bit.ly/lCOPI Medication Guide: bit.ly/lCOMEDG Important Safety Information: ht...
MANKIND PHARMA LTD
Phase 3, New Delhi, IN
Last Update: 04/04/2026
Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating...
Compliance Ranges Comparison
ICOTYDE™ (icotrokinra) tablets for US HCPs
MANKIND PHARMA LTD
Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for ICOTYDE™ (icotrokinra) tablets for US HCPs in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for MANKIND PHARMA LTD in 2026.
Incident History - ICOTYDE™ (icotrokinra) tablets for US HCPs (X = Date, Y = Severity)
ICOTYDE™ (icotrokinra) tablets for US HCPs cyber incidents detection timeline including parent company and subsidiaries.
Incident History - MANKIND PHARMA LTD (X = Date, Y = Severity)
MANKIND PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents
ICOTYDE™ (icotrokinra) tablets for US HCPs
MANKIND PHARMA LTD
FAQ
Latest Global CVEs
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an inadequate encryption strength vulnerability which could allow an attacker to steal admin credentials via weak hash or a pass-the-hash attack.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could allow for asset discovery by unauthenticated users.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.
Pronetiqs IntraVUE Versions 3.2.1a14 and prior have a plaintext storage of a password vulnerability that could expose cleartext credentials through the API.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could expose the underlying host/share filesystem.